These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6892833)

  • 21. Factors influencing the relationship between labelled triiodothyronine and thyroxine levels in the serum of patients with Graves' disease.
    Földes J; Gyertyánfy G; Tako J; Bános C; Gesztesi E
    Endokrinologie; 1973 Jan; 61(1):52-64. PubMed ID: 4739850
    [No Abstract]   [Full Text] [Related]  

  • 22. [Triiodothyronine-thyrotoxicosis].
    Lande G; Kjolseth I
    Tidsskr Nor Laegeforen; 1972 Dec; 92(35):2424-7. PubMed ID: 4678982
    [No Abstract]   [Full Text] [Related]  

  • 23. Triiodothyronine antibodies in a case of Graves' disease: long-term follow-up under carbimazole.
    Heshmati HM; Izembart M; Turpin G; Vallée G
    Horm Metab Res; 1991 Mar; 23(3):148. PubMed ID: 1864563
    [No Abstract]   [Full Text] [Related]  

  • 24. Low response of the thyroid gland to endogenous thyrotropin increased by thyrotropin-releasing hormone in patients with euthyroid Graves' disease.
    Kashiwai T; Tada H; Watanabe Y; Shimaoka Y; Yagoro A; Hidaka Y; Fujikado T; Amino N
    Thyroid; 1998 Oct; 8(10):881-5. PubMed ID: 9827654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transient recurrence of hyperthyroidism after delivery in Graves' disease.
    Amino N; Miyai K; Yamamoto T; Kuro R; Tanaka F
    J Clin Endocrinol Metab; 1977 Jan; 44(1):130-6. PubMed ID: 576228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genes that characterize T3-predominant Graves' thyroid tissues.
    Matsumoto C; Ito M; Yamada H; Yamakawa N; Yoshida H; Date A; Watanabe M; Hidaka Y; Iwatani Y; Miyauchi A; Takano T
    Eur J Endocrinol; 2013 Feb; 168(2):137-44. PubMed ID: 23109646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperthyroidism of Graves' disease: evidence for only unilateral involvement of the thyroid gland in a 31-year-old female patient.
    Dimai HP; Ramschak-Schwarzer S; Lax S; Lipp RW; Leb G
    J Endocrinol Invest; 1999 Mar; 22(3):215-9. PubMed ID: 10219891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in thyroid function in euthyroid subjects with a family history of Graves' disease: a follow-up study of 69 patients.
    Tamai H; Ohsako N; Takeno K; Fukino O; Takahashi H; Kuma K; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1980 Nov; 51(5):1123-7. PubMed ID: 6774999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyroid hormone autoantibodies in patients with untreated Graves' disease: with special reference to age.
    Nakamura S; Hattori J; Ogawa T; Sakata S
    Endocr J; 1993 Jun; 40(3):337-42. PubMed ID: 7920887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism.
    Martino E; Balzano S; Bartalena L; Loviselli A; Sica V; Petrini L; Grasso L; Piga M; Braverman LE
    J Endocrinol Invest; 1991 Nov; 14(10):847-51. PubMed ID: 1687043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
    Yamada T; Koizumi Y; Sato A; Hashizume K; Aizawa T; Takasu N; Nagata H
    J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelial hyperplasia and decreased colloid content of the thyroid gland in triiodothyronine-predominant Graves' disease.
    Takamatsu J; Takeda K; Katayama S; Sakane S; Morita S; Kuma K; Ohsawa N
    J Clin Endocrinol Metab; 1992 Oct; 75(4):1145-50. PubMed ID: 1400885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Responses to TRH and T3 suppression tests in euthyroid subjects with a family history of Graves' disease.
    Tamai H; Suematsu H; Ikemi Y; Kuma K; Matsuzuka F; Kumagai LF; Shizume K; Nagataki S
    J Clin Endocrinol Metab; 1978 Sep; 47(3):475-9. PubMed ID: 122407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of T cell subset imbalance in relatives of Graves' disease patients.
    Biassoni P; Ciprandi G; Ferrini S; Chimini G; Canonica GW; Bagnasco M
    J Endocrinol Invest; 1984 Apr; 7(2):141-5. PubMed ID: 6609952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W; Man N; Li YS; Shan ZY; Teng WP
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triiodothyronine autoantibodies in Graves' disease: their changes after antithyroid therapy and relationship with the thyroglobulin antibodies.
    Wang PW; Huang MJ; Liu RT; Chen CD
    Acta Endocrinol (Copenh); 1990 Jan; 122(1):22-8. PubMed ID: 1689529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in thyroid volume during antithyroid drug therapy for Graves' disease and its relationship to TSH receptor antibodies, TSH and thyroglobulin.
    Yamaguchi Y; Inukai T; Iwashita A; Nishino M; Yamaguchi T; Shohda Y; Shimomura Y; Ohshima K; Kobayashi S; Kobayashi I
    Acta Endocrinol (Copenh); 1990 Oct; 123(4):411-5. PubMed ID: 1978459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of alterations in circulating thyroglobulin, triiodothyronine and thyroxine in response to exogenous (bovine) and endogenous (human) thyrotropin.
    Uller RP; Van Herle AJ; Chopra IJ
    J Clin Endocrinol Metab; 1973 Nov; 37(5):741-5. PubMed ID: 4800435
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
    Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
    Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.